Australia to sell biggest health insurer

The conservative government of Prime Minister Tony Abbott on Wednesday said it would press ahead with the sale of Australia's largest health insurer Medibank Private via an initial public offering.

Medibank welcomed the announcement which reports said could value the provider at up to Aus$4 billion (US$3.7 billion).

"Subject to market conditions, Medibank Private will be sold through an in the 2014-15 financial year," Finance Minister Mathias Cormann said, with the proceeds going towards infrastructure projects.

Cormann refused to comment on the amount the sale would generate, and said the precise timing and structure of the IPO were yet to be determined.

He also would not comment on which other public assets might be sold to pay down debt as part of a government-wide audit to eliminate wasteful spending.

The minister said an independent scoping study had confirmed the government's view that there were no compelling reasons for it to own Medibank which provides cover to some 3.8 million people.

"The sale of Medibank will remove the inherent conflict currently in place where the government is both the market regulator and the owner of a large participant in the market," he said.

Cormann said Medibank was one of 34 competing funds in the private health insurance in Australia, and the scoping study found no evidence that premiums would rise as a result of the sale.

Medibank managing director George Savvides assured members that the brand would not change as a result of the IPO.

"We welcome the government's decision today, we're 37 years old, we have a wonderful inheritance and a brand that people trust," he said.

"Let me reassure you that the Medibank Australians have trusted for years is the very same Medibank that will continue to look after your health well into the future."

Medibank made Aus$315 million profit last year. It is the only asset the government has spoken about selling.

New Zealand has decided to sell stakes in energy companies and flag carrier Air New Zealand as part of a plan to raise US$4.2-5.9 billion from asset sales and return the budget to surplus by 2014-15.

add to favorites email to friend print save as pdf

Related Stories

French stimulus plan focuses on new technology

Jul 09, 2013

The French government has unveiled a modest stimulus plan focusing on new technology and ecology, in an attempt to boost an economy that's back in recession and is weighing on overall European prospects.

Australian parties snub tobacco money

Aug 22, 2013

Australia's ruling Labor party pledged a ban on tobacco company donations if returned to office Thursday and the conservatives followed suit, ordering an end to campaign funds from cigarette firms.

Twitter accused of ruse to pump up share price (Update)

Oct 30, 2013

Two financial firms sued Twitter on Wednesday, saying it supported their own world tour to sell its shares last year, only to disallow the sales in a ruse aimed at boosting the company's valuation above $10 billion for an ...

Recommended for you

Using feminist theory to understand male rape

7 hours ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments